U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs - 08/05/2020 - 08/05/2020
  1. FDA Meetings, Conferences and Workshops

Workshop | In Person

Event Title
Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs
August 5, 2020

Scheduled

Public Workshop

Date:
August 5, 2020

DESCRIPTION/SUMMARY

This public workshop is currently being scheduled and planned as a virtual meeting. The Food and Drug Administration is announcing a public workshop coccidioidomycosis (Valley Fever) to discuss coccidioidomycosis, current state and clinical disease and trial design considerations for developing antifungal drugs.

ABOUT THE PUBLIC WORKSHOP

FDA is announcing a virtual public workshop for coccidioidomycosis (Valley Fever) pertaining to landscape and considerations for developing antifungal drugs. Discussions will focus on the current state and clinical trial design considerations related to coccidioidomycosis and include the following topic areas:

  • Current state regarding epidemiology and vaccine development
  • Diagnostics
  • Disease manifestations
  • Trial designs for antifungal drug development, including populations and endpoints
  • Resources for product development and future needs

Registration

This meeting will be held in virtual format only. Registration is required for online attendance and will be available until 5:00 pm on August 3, 2020.

To register for this workshop, visit https://www.eventbrite.com/e/coccidioidomycosis-valley-fever-landscape-and-considerations-workshop-tickets-95250608133

REQUEST FOR ORAL PRESENTATIONS

During online registration you may indicate if you wish to present during a public comment session and which topic(s) you wish to address during the registration process here. We will do our best to accommodate requests to make public comments. We will determine the amount of time allotted to each presenter and the approximate time each oral presentation is to begin and will select and notify participants by July 22, 2020. All requests to make oral presentations must be received by July 15, 2020. If selected for presentation, any presentation materials must be emailed to ONDPublicMTGSupport@fda.hhs.gov no later than July 29, 2020.

ONLINE ATTENDANCE (WEBCAST)

This meeting will be available for online viewing, on the day of the meeting via the following link:
https://collaboration.fda.gov/antifungaldrugs080520/.

If you have never attended a Connect Pro event before, test your connection at
https://collaboration.fda.gov/common/help/en/support/meeting_test.htm.

To get a quick overview of the Connect Pro program, visit
https://www.adobe.com/go/connectpro_overview .

EVENT POINT OF CONTACT

Antoinette Ziolkowski, at Antoinette.Ziolkowski@fda.hhs.gov Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, rm. 6221, Silver Spring, MD 20993-0002, 301-796-1300.

WEBCAST RECORDING

Back to Top